Evidence map›Paper›PMID 26342659›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Cancer targeted therapeutics: From molecules to drug delivery vehicles.

Daxing Liu, Debra T Auguste

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daxing LiuDepartment of Biomedical Engineering, The City College of New York, New York, NY 10031, United States.
Debra T AugusteDepartment of Biomedical Engineering, The City College of New York, New York, NY 10031, United States. Electronic address: dauguste@ccny.cuny.edu.

Funding

Personalized Therapeutics for Inhibiting Breast Cancer MetastasisDP2CA174495 · NCI · NORTHEASTERN UNIVERSITY · PI AUGUSTE, DEBRA · 2012 to 2017
$2.8M
NCI NIH HHS DP2 CA174495
6 · The paper itself

Abstract

The pitfall of all chemotherapeutics lies in drug resistance and the severe side effects experienced by patients. One way to reduce the off-target effects of chemotherapy on healthy tissues is to alter the biodistribution of drug. This can be achieved in two ways: Passive targeting utilizes shape, size, and surface chemistry to increase particle circulation and tumor accumulation. Active targeting employs either chemical moieties (e.g. peptides, sugars, aptamers, antibodies) to selectively bind to cell membranes or responsive elements (e.g. ultrasound, magnetism, light) to deliver its cargo within a local region. This article will focus on the systemic administration of anti-cancer agents and their ability to home to tumors and, if relevant, distant metastatic sites.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic AgentsHumansNeoplasmsAntineoplastic AgentsActive targetingIntegrated targetingPassive targetingPharmacologic targetingTargeted drug delivery

Identifiers

PMID26342659
PMCPMC5503194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.